Back to search

Belgium· BE-AMP-SAM526133-00

Adynovi 250 IU/2 ml

A medicinal product containing rurioctocog alfa pegol, registered in Belgium by Baxalta Innovations.

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedAdynovi 250 IU/2 mlATC—REGISTER NO.BE-AMP-SAM526133-00PACKS LISTED0CHECKEDSeptember 26, 2026

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Rurioctocog Alfa Pegol
Manufacturer
Baxalta Innovations
Country
Belgium (BE)
ATC code
—
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0686b21d-3d02-4122-bd9d-f5e703385803
GET /v1/drugs/0686b21d-3d02-4122-bd9d-f5e703385803?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Adynovi 250 IU/2 ml",
  "name_fr": "Adynovi 250 IU/2 ml",
  "name_nl": "Adynovi 250 IU/2 ml",
  "amp_code": "SAM526133-00",
  "strengths": [
    "250.0000"
  ],
  "pack_count": 0,
  "substances": [
    "Rurioctocog Alfa Pegol"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": null,
  "authorisation_numbers": null
}

See everything about rurioctocog alfa pegol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.